BBIO
Jefferies is still in the BBIO bull camp
Jefferies reiterated a Buy on BridgeBio Pharma and kept its $100 price target intact, which is basically the Street’s way of saying, “yes, this one’s been ripping, and no, we’re not getting less excited.” The stock was trading around $77.70, already up more than 126% over the past year, so this isn’t exactly a hidden gem anymore.
The real story: April 30 could matter a lot
The firm thinks Attruby sales in ATTR-CM could come in above the $173 million consensus when BridgeBio reports first-quarter earnings on April 30. For investors, that’s the kind of setup that can turn a good biotech story into a very loud one — especially when the market is already leaning in and expecting growth.
Why the legal stuff matters too
Jefferies also flagged a five-day court case starting April 27 involving Pfizer’s tafamidis versus generics. That matters because any ruling in the second half of 2026 — or even an early settlement — could swing the value investors assign to Attruby. In biotech, courtroom drama can act like an invisible hand on the valuation model.
More pipeline, more optionality
BridgeBio’s pitch isn’t just one drug and a prayer. Jefferies pointed to BBP-418, Encaleret, and Infigratinib as part of a broader rare-disease pipeline with more than $9 billion in valuation support. So if you’re trying to figure out why analysts keep circling this name, it’s because the company is starting to look less like a one-hit wonder and more like a playlist.
Big picture: BridgeBio is heading into earnings with momentum, analyst support, and a few pipeline catalysts that could keep the stock volatile in the fun way — or the terrifying way, depending on how you feel about biotech.